苏木乙酸乙酯对急性冠脉综合征外周血CD4+T淋巴细胞增殖及Th17/Treg平衡的影响
|
摘要
目的观察苏木乙酸乙酯提取液(SAEE)对急性冠脉综合征患者外周血CD4+T淋巴细胞的体外增殖及Th17/Treg比例的影响。方法通过SAEE干预急性冠脉综合征患者外周血单个核细胞,以稳定型心绞痛患者作为对照。运用MTT法检测外周血CD4+T淋巴细胞的增殖,流式细胞术检测Th17、Treg百分比含量,RT-PCR检测白细胞介素-17A(IL-17A) mRNA、叉头翼状螺旋转录因子3(Foxp3) m RNA的表达。结果与稳定型心绞痛患者比较,急性冠脉综合征患者CD4+T淋巴细胞体外增殖能力显著增加,IL-17A的表达显著增加,Foxp3的表达显著降低,Th17/Treg比值显著增高,差异均具有统计学意义(P <0.01);与急性冠脉综合征组比较,SAEE能够显著抑制CD4+T淋巴细胞体外增殖能力,降低IL-17A的表达,升高Foxp3的表达,调控Th17/Treg的比值,其中以苏木乙酸乙酯高剂量组效果最佳,差异均具有统计学意义(P <0.01)。结论SAEE能够通过抑制外周血CD4+T淋巴细胞增殖,调控Th17/Treg的平衡,达到抑制免疫反应和抗动脉硬化的作用。
Objective: To observe the effect of sppan acetic ether extract on the proliferation of CD4+T lymphocytes and the ratio of Th17/Treg of peripheral blood in patients with acute coronary syndrome. Methods: Sppan acetic ether extract was used to intervene peripheral blood mononuclear cells in patients with acute coronary syndrome,and stable angina pectoris was used as control. MTT assay was used to detect the proliferation of peripheral blood CD4+T lymphocytes,flow cytometry to detect the percentage of Th17 and Treg,and RT-PCT to detect the expression of IL-17 A mRNA and Foxp3 mRNA. Results: Compared with patients with stable angina pectoris,the proliferation ability of CD4+T lymphocytes,the expression of IL-17 A and the ratio of Th17/Treg were significantly increased,and the expression of Foxp3 were significantly reduced(P < 0.01). Sppan acetic ether extract could inhibit the proliferation of CD4 +T lymphocytes in vitro,decrease the expression of IL-17 A,increase the expression of Foxp3,and regulate the ratio of Th17/Treg,compared with acute coronary syndrome group. The effect of Sppan acetic ether extract in high dose group was the best(P < 0.01). All defferences above were statistically significant(P < 0.01). Conclusion: Sppan acetic ether extract can inhibit immune response and anti-atherosclerosis by inhibiting the proliferation of peripheral blood CD4+T lymphocytes and regulating the balance of Th17/Treg.
Objective: To observe the effect of sppan acetic ether extract on the proliferation of CD4+T lymphocytes and the ratio of Th17/Treg of peripheral blood in patients with acute coronary syndrome. Methods: Sppan acetic ether extract was used to intervene peripheral blood mononuclear cells in patients with acute coronary syndrome,and stable angina pectoris was used as control. MTT assay was used to detect the proliferation of peripheral blood CD4+T lymphocytes,flow cytometry to detect the percentage of Th17 and Treg,and RT-PCT to detect the expression of IL-17 A mRNA and Foxp3 mRNA. Results: Compared with patients with stable angina pectoris,the proliferation ability of CD4+T lymphocytes,the expression of IL-17 A and the ratio of Th17/Treg were significantly increased,and the expression of Foxp3 were significantly reduced(P < 0.01). Sppan acetic ether extract could inhibit the proliferation of CD4 +T lymphocytes in vitro,decrease the expression of IL-17 A,increase the expression of Foxp3,and regulate the ratio of Th17/Treg,compared with acute coronary syndrome group. The effect of Sppan acetic ether extract in high dose group was the best(P < 0.01). All defferences above were statistically significant(P < 0.01). Conclusion: Sppan acetic ether extract can inhibit immune response and anti-atherosclerosis by inhibiting the proliferation of peripheral blood CD4+T lymphocytes and regulating the balance of Th17/Treg.
引文
[1]石金河,陈希妍,任芳,等.两种剂量阿托伐他汀治疗老年急性冠脉综合征的疗效及对炎症和凝血因子的影响[J].中国老年学,2014,34(2):510-511.
[2]李金萍,巨名飞,陈立.炎症因子与急性冠脉综合征关系的研究现状[J].河北医学,2015,21(6):1008-1010.
[3]邢露茗,张芯,李光,等.苏木乙酸乙酯提取物对动脉粥样硬化模型大鼠血清MCP-1的影响[J].中医药信息,2013,30(2):104-105.
[4]张芯,杨建飞,邢露茗,等.苏木乙酸乙酯提取物对动脉粥样硬化模型大鼠血清MIP-1β的影响[J].中医药信息,2013,30(4):22-24.
[5]李光,杨建飞,张芯,等.苏木乙酸乙酯提取物对动脉粥样硬化模型大鼠血清hs-CRP的影响[J].中医药学报,2013,41(4):23-24.
[6]汪洋,周亚滨.苏木乙酸乙酯提取物对大鼠外周血细胞因子的影响[J].中医药信息,2013,30(1):13-15.
[7]刘志平,张晶,陈会君.苏木乙酸乙酯提取物对慢性病毒性心肌炎模型小鼠T细胞亚群的影响[J].中医药信息,2015,32(2):22-24.
[8]张艳平,丁矢.急性冠状动脉综合征患者Th17和Treg细胞的变化检测[J].中国医药指南,2012,10(3):103-104.
[9] Amsterdam EA,Wenger NK,Brindis RG,et al. 2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014,64(24):e139-e228.
[10] Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC).ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J, 2012, 33(20):2569-2619.
[11]中华医学会心血管病学分会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[12]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2014》概要[J].中国循环杂志,2015,30(7):617-622.
[13]徐学彬,张卫娟,汪蛟龙,等.急性冠脉综合症患者冠脉病变与颈动脉斑块的相关性分析[J].中国民族民间医药,2013,22(16):35-36.
[14] Fox KA,Carruthers KF,Dunbar DR,et al. Underestimated and under-recognized:the late consequences of acute coronary syndrome(GRACE UK-Belgian Study)[J]. Eur Heart J,2010,31(22):2755-2764.
[15]郑昊钏,龙芳,杨华,等.急性冠脉综合征的发病机制及治疗进展[J].中国药房,2014,25(30):2846-2848.
[16]孙建平,涂晓龙,仇玉乎,等.急性冠脉综合征的研究进展[J].中西医结合心脑血管病杂志,2008,6(7):820-822.
[17]王治校,王洁,何茜,等.急性冠脉综合征患者体内CD4+CD25+Foxp3+调节性T细胞的变化及阿托伐他汀对其影响[J].湖北医药学院学报,2017,36(1):40-44.
[18] Zhou X,Robertson AKL,Hjerpe C,et al. Adoptive transfer of CD4+T cells reactive to modified low-density lipoprotein aggravates atherosclerosis[J]. Arterios Thromb Vasc Biol,2006,26(4):864-870.
[19]赵朝,杨小波,袁祖贻,等.急性冠脉综合征患者Th17和Treg细胞的检测及意义[J].中国免疫学杂志,2011,27(6):560-564.
[20]陈刚,吴旭,王镇波,等.急性冠脉综合征患者CD4+T淋巴细胞亚群的变化及临床意义[J].现代生物医学进展,2015,15(11):2089-2091.
[21] Fontenot JD,Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+regulatory T cells[J]. Nat Immunol,2003,4(4):330-336.
[2]李金萍,巨名飞,陈立.炎症因子与急性冠脉综合征关系的研究现状[J].河北医学,2015,21(6):1008-1010.
[3]邢露茗,张芯,李光,等.苏木乙酸乙酯提取物对动脉粥样硬化模型大鼠血清MCP-1的影响[J].中医药信息,2013,30(2):104-105.
[4]张芯,杨建飞,邢露茗,等.苏木乙酸乙酯提取物对动脉粥样硬化模型大鼠血清MIP-1β的影响[J].中医药信息,2013,30(4):22-24.
[5]李光,杨建飞,张芯,等.苏木乙酸乙酯提取物对动脉粥样硬化模型大鼠血清hs-CRP的影响[J].中医药学报,2013,41(4):23-24.
[6]汪洋,周亚滨.苏木乙酸乙酯提取物对大鼠外周血细胞因子的影响[J].中医药信息,2013,30(1):13-15.
[7]刘志平,张晶,陈会君.苏木乙酸乙酯提取物对慢性病毒性心肌炎模型小鼠T细胞亚群的影响[J].中医药信息,2015,32(2):22-24.
[8]张艳平,丁矢.急性冠状动脉综合征患者Th17和Treg细胞的变化检测[J].中国医药指南,2012,10(3):103-104.
[9] Amsterdam EA,Wenger NK,Brindis RG,et al. 2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014,64(24):e139-e228.
[10] Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC).ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Eur Heart J, 2012, 33(20):2569-2619.
[11]中华医学会心血管病学分会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[12]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2014》概要[J].中国循环杂志,2015,30(7):617-622.
[13]徐学彬,张卫娟,汪蛟龙,等.急性冠脉综合症患者冠脉病变与颈动脉斑块的相关性分析[J].中国民族民间医药,2013,22(16):35-36.
[14] Fox KA,Carruthers KF,Dunbar DR,et al. Underestimated and under-recognized:the late consequences of acute coronary syndrome(GRACE UK-Belgian Study)[J]. Eur Heart J,2010,31(22):2755-2764.
[15]郑昊钏,龙芳,杨华,等.急性冠脉综合征的发病机制及治疗进展[J].中国药房,2014,25(30):2846-2848.
[16]孙建平,涂晓龙,仇玉乎,等.急性冠脉综合征的研究进展[J].中西医结合心脑血管病杂志,2008,6(7):820-822.
[17]王治校,王洁,何茜,等.急性冠脉综合征患者体内CD4+CD25+Foxp3+调节性T细胞的变化及阿托伐他汀对其影响[J].湖北医药学院学报,2017,36(1):40-44.
[18] Zhou X,Robertson AKL,Hjerpe C,et al. Adoptive transfer of CD4+T cells reactive to modified low-density lipoprotein aggravates atherosclerosis[J]. Arterios Thromb Vasc Biol,2006,26(4):864-870.
[19]赵朝,杨小波,袁祖贻,等.急性冠脉综合征患者Th17和Treg细胞的检测及意义[J].中国免疫学杂志,2011,27(6):560-564.
[20]陈刚,吴旭,王镇波,等.急性冠脉综合征患者CD4+T淋巴细胞亚群的变化及临床意义[J].现代生物医学进展,2015,15(11):2089-2091.
[21] Fontenot JD,Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+regulatory T cells[J]. Nat Immunol,2003,4(4):330-336.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |